Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

Couturier, Jérôme; Vincent‐Salomon, Anne; André, Nathalie; Beuzeboc, Philippe; Mouret, E; Zafrani, B; Sastre-Garau, Xavier

doi:10.1038/modpathol.3880228

Cited by 104 publications

(78 citation statements)

References 28 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Our result of 13.2% HER-2 protein overexpression in breast cancer is in the lower range of published results for FDA approved reagents (13-30% positive). [24][25][26] However, the strong correlation found between IHC and FISH in our breast cancer samples was exactly as described in the literature 27,28 ( Figure 1). This confirms the validity of our assays.…”

Section: Discussionsupporting

confidence: 90%

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

et al. 2007

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

et al. 2007

View full text Add to dashboard Cite

“…Two different signal distribution patterns have been observed, either consistent signal clusters or individual scattered signals. Signal distribution as groups or clusters has been described previously by others using FISH for the detection of HER2 (Couturier et al, 2000;Pauletti et al, 1996;Press et al, 1997). Even though double minute chromosomes have been shown to have a tendency to aggregate, this pattern is more likely a result of intrachromosomal amplification, namely homogeneously staining regions (Cowell, 1982).…”

Section: Discussionmentioning

confidence: 98%

Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma

Dandachi

Dietze

Hauser‐Kronberger

2002

Laboratory Investigation

112

View full text Add to dashboard Cite

SUMMARY:The high incidence of HER2 overexpression on the cell surface of breast cancer cells and the recognized prognostic and potentially predictive value of HER2 render this cell surface receptor a novel and important therapeutic target. Although immunohistochemistry (IHC; HercepTest) and fluorescence in situ hybridization (FISH; PathVysion and INFORM)-both approved by the Food and Drug Administration-have emerged as the most viable assays for evaluation of HER2 status in routine clinical practice, there is still no consensus on which is the best method for assessing HER2 status. Therefore, our specific objective was to establish a chromogenic in situ hybridization (CISH) assay for the detection of HER2 amplification on a cohort of 173 archival invasive breast carcinomas. Results were compared with HercepTest, which is the most frequently used method for detecting HER2 alteration. Additionally, HER2 gene copy number was investigated using differential PCR (dPCR) as a testing system. HER2 overexpression was found by IHC in 24.3%; HER2 amplification was found by CISH in 19.1% and by dPCR in 9.2% of the tumors. The overall concordance rate was 95.9% between CISH and IHC and 85.0% between dPCR and IHC. Kappa statistics revealed an excellent agreement between IHC and CISH ( ϭ 0.878), but only a moderate agreement was found between IHC and dPCR ( ϭ 0.482). Discrepant cases between CISH and HercepTest and all IHC-positive cases (ϩ2 and ϩ3), a total of 42 cases, were analyzed with the FISH PathVysion (Vysis) assay. Among 25 HercepTest-positive cases (score ϩ3), 2 showed no gene amplification by FISH or CISH. Four of 13 tumors with weak HER2 overexpression (score ϩ2) were negative with both FISH and CISH. Concordance between CISH and FISH was 100% for the 38 cases analyzed. The current study showed that CISH represents a practical and simple assay for evaluating HER2 gene amplification in archival material, offering a promising alternative to IHC or FISH for the routine diagnostic setting. (Lab Invest 2002, 82:1007-1014.

show abstract

“…Immunohistochemical procedures for the analysis of HER2 expression were defined to provide a strong correlation between HER2 overexpression and gene amplification status, as determined by FISH (Couturier et al, 2000). After rehydration and antigenic retrieval in citrate buffer (10 mM, pH 6.1), tissue sections were incubated with the CB11 anti-p185 HER/neu monoclonal antibody (Novocastra, Newcastle UK), for 1 h, at 1/800 dilution.…”

Section: Her2 Statusmentioning

confidence: 99%

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

et al. 2007

View full text Add to dashboard Cite

Discrepancies have been reported between HER2 status in primary breast cancer and micrometastatic cells in bone marrow. The aim of this study was to assess HER2 gene status in micrometastatic cells in bone marrow and corresponding primary tumour. Micrometastatic cells were detected in bone marrow aspirations in a prospective series of 27 breast cancer patients by immunocytochemistry (pancytokeratin antibody). HER2 status of micrometastatic cells was assessed by fluorescence in situ hybridisation (FISH), respectively in 24 out of 27. Primary tumour HER2 status was assessed by immunohistochemistry (CB11 antibody) and by FISH in 20 out of 27 of the cases. HER2 was amplified or overexpressed in five out of 27 (18.5%) primary tumours and in four out of 27 (15%) micrometastatic cells. In two cases, HER2 was overexpressed and amplified in primary tumour, but not in micrometastatic cells, whereas, in one case, HER2 presented a low amplification rate (six copies) in micrometastatic cells not found in the primary tumour. We demonstrated that negative and positive HER2 status remained, in the majority of the cases, stable between the bone marrow micrometastasis and the primary tumour. Therefore, the efficiency of anti-HER2 adjuvant therapy could be evaluated, in a clinical trial, by sequential detection of HER2-positive micrometastatic cells within the bone marrow, before and after treatment.

show abstract

Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

Abstract: ERBB2 (HER-2

Cited by 104 publications

References 28 publications

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin

Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

Contact Info

Product

Resources

About